Clovis Oncology Inc (NASDAQ: CLVS) announced today that the leading scientific site for the Phase 1/2 LuMIERE study of FAP-2286 is now available at the O’NealO’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham (UAB).
The O’Neal Comprehensive Cancer Center at UAB is amongst the country’s foremost cancer investigation establishments and one of only 51 all-inclusive cancer centers selected by the National Cancer Institute.
Phase 1 portion of the study to evaluate the safety of FAP-targeting investigational therapeutic agent
The Phase 1 section of the LuMIERE investigation will assess the security of the FAP-targeting investigational healing agent and ascertain the suggested Phase 2 dosage and schedule of lutetium-177 labeled FAP-2286. FAP-2286 branded with gallium-68 will be used as an investigational imaging agent to classify patients with FAP-positive cancers suitable for treatment with the therapeutic agent. Once the Phase 2 dosage is established, Phase 2 development cohorts are intended in various tumor kinds.
“We are satisfied to begin backed scientific progress of FAP-2286 with the LuMIERE study founded on the scientific community’s eagerness to further discover the capacity of targeted radionuclide therapy and FAP as a healing objective,” said Patrick J. Mahaffy, President, and CEO of Clovis Oncology. “Assumed FAP is tremendously articulated in many of the hardest-to-treat rock-hard growths, we look forward to inspecting the capability of FAP-2286 to treat patients with cancer as our main entry points into this evolving arena of directed radiotherapy. The O’NealO’Neal Comprehensive Cancer Center and each of the scientific trial sites projected to open for registration shortly bring marvelous nuclear medicine and medical oncology know-how as well as the hunger for the program.”
FAP is a cell-surface protein
FAP is a cell-surface protein conveyed in limited quantities by normal tissues but extremely conveyed in cancer-associated fibroblasts (CAFs) existent in the tumor microenvironment of many dense tumors. Lu-FAP-2286 strongly and selectively fixes FAP on the exterior of CAFs and tumor cells to distribute the beta particle-emitting radioisotope Lu, ensuing in DNA injury and cell demise.